NICE Makes New Round of COVID-19 Drug Approval Recommendations

The UK’s NICE has announced its recommendations of approval for three COVID-19 drugs and the rejection of five others based on value and efficacy data. Paxlovid, RoActemra, and Olumiant from Pfizer, Roche, and Eli Lilly, respectively, made the cut. Uncertain efficacy data and pricing issues sank the applications of drugs from Merck, Gillead, GSK, Regeneron, and AstraZeneca

According to Phil Taylor, “The guidance is out for comment until 7 December, ahead of a second evaluation committee meeting scheduled for 24 January next year. The expected publication date for the finalised document is 29 March.”

To read more, click here.

(Source: Pharma Phorum, November 16^th, 2022)